News

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy
Investing.com -- BiomX (NYSE: PHGE) Inc. (NYSE American:PHGE) stock surged 60% after the clinical-stage company announced it has successfully initiated patient dosing in its Phase 2b trial evaluating ...
The Manila Times6d
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
First patient dosing in Company’s Phase 2b trial marks pivotal milestone in phage therapy development program targeting ...